Disappointing scores show that medical affairs teams need to up their game The medical oncologists we surveyed say that medical affairs teams for cancer pain drugs turned in a lacklustre performance in the past 6 months...

Gain new KOL insights on the latest events that have the potential to impact the treatment landscape of ulcerative colitis (UC). Topics covered include expert opinions on: Takeda announcing the presentation of real-world...

Is patient preference costing your brand market share? Market barriers affect nearly 15% of Parkinson’s disease prescriptions in the EU5 countries, causing half of the 8 brands we surveyed to lose market share...

Are high cost and market access problems costing your brand market share? Are market barriers holding your brand back? According to our survey of US-based neurologists, 8 of the 11 Parkinson’s disease treatments...

How are market barriers moving the goalposts for CLL drugs in Europe? Just how significantly are market barriers skewing prescribing behaviour for CLL drugs in Europe? One drug is clearly popular and others are playing...

Leading brands have room to grow At least 30% of the haematologists we surveyed don’t prescribe the 7 leading haemophilia B treatments we asked them about. But most are willing to consider them, so there’s...

Losing share to competitors? Understanding market barriers can help close the gap Haemophilia A treatment is a highly competitive market in the EU5 countries, where market shares for several of the brands we surveyed...

Why are some US GHD brands standing out more than others?  There are various options available to US endocrinologists to treat growth hormone deficiency (GHD). Clearly some of these options are achieving greater...